Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
ImmusanT
About
ImmusanT is a biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Health Diagnostics,Therapeutics
- Founded date
- Jun 8, 2011
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy.ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 14, 2017 | Series C | $40M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
Yes | Series C |
